摘要
目的:观察131I肿瘤细胞核人鼠嵌合单克隆抗体注射液(131I-chTNT)对晚期肺癌的临床疗效,探讨晚期肺癌治疗的新方法。方法:选取2006年6月-2007年6月我院收治的13例经病理证实的晚期肺癌,予以131I-chTNT抗体放射免疫治疗。每次静滴131I-chTNT抗体50mCi,3周-4周后再用1次,每次治疗10天后行ECT检查131I-chTNT在体内的分布。对照组为16例行普通化疗的患者。结果:完全缓解(CR)1例,部分缓解(PR)3例,无变化(NR)8例,进展(PD)1例,总有效率30.76%。与对照组有显著性差异(P<0.05)。结论:131I-chTNT作为一种新型放射免疫治疗药物,毒副作用较小,对晚期难治性肺癌治疗有一定的疗效。
Objective ： To analyze the clinical efficacy of 131Ⅰ - chTNT radioimmunotherapy in advanced lung cancer, and investigate new therapeutic method for advanced lung carcinoma. Methods： Thirteen patients with advanced lung cancer were treated with 131Ⅰ -chTNT radioimmunotherapy at the dose of 50mCi 131Ⅰ -chTNT antibody intravenous injection once time, and after 3 -4 weeks, injected another time with same dose. Distribution of 131Ⅰ - chTNT in the body was detected by ECT 10 days after each injection. Results： Of the 13 patients, complete remission in 1 patient, partial remission in 3 patients, failed response in 8 patients, and progressed in 1 patient, total efficiency rate was 30.76%. Conclusion： 131Ⅰ -chTNT as a new drug of radioimmunotherapy, was effective in advanced lung cancer with less adverse responses.
出处
《现代肿瘤医学》
CAS
2008年第9期1526-1528,共3页
Journal of Modern Oncology
